Regenerative Medicine
Advanced injection therapy for knee osteoarthritis relief.
Available at these clinics:
Mississauga
Oakville
At MedCAiRE Health, we proudly offer nSTRIDE® APS (Autologous Protein Solution)—a cutting-edge injectable treatment designed to relieve knee osteoarthritis pain by reducing inflammation at its biological source. Using a Zimmer Biomet centrifuge and guided by real-time ultrasound, this single-injection solution offers long-lasting relief and cartilage protection.
nSTRIDE is an autologous biologic therapy that concentrates powerful anti-inflammatory proteins and growth factors from your own blood. These proteins are processed into a solution that is injected directly into your knee joint—using ultrasound guidance for maximum accuracy.
⚠️ nSTRIDE is not a steroid or lubricant, but a biologically targeted solution aimed at interrupting the inflammatory cascade that causes cartilage deterioration in knee osteoarthritis.
At MedCAiRE, all nSTRIDE injections are performed under ultrasound guidance to ensure:
📸 X-ray imaging also helps us confirm osteoarthritis severity and joint anatomy before proceeding.
✔️ Long-lasting pain relief (6–12 months or more)
✔️ Improved joint function and daily mobility
✔️ Targets inflammation at the molecular level
✔️ Single, ultrasound-guided injection
✔️ Non-surgical, natural, and autologous (from your own blood)
A detailed evaluation of your knee is performed, including an ultrasound exam to assess joint structure and OA severity.
A small blood sample is processed in our on-site Zimmer Biomet centrifuge to create the autologous protein solution (APS).
The APS is precisely injected into your knee joint under real-time ultrasound guidance, ensuring proper delivery.
You may resume light activity within 24–48 hours. A personalized rehab plan may be provided.
💲 nSTRIDE® APS Single Injection (Ultrasound-Guided): $1245 CAD
(Includes Zimmer Biomet processing, diagnostic ultrasound, ultrasound-guided injection, and follow-up care.)
You may benefit from nSTRIDE if you:
nSTRIDE has been studied in multiple international clinical trials and has shown:
Most patients tolerate the procedure well. We use local anesthetic and ultrasound guidance to ensure comfort and precision.
nSTRIDE is designed as a single-injection treatment. Some patients may benefit from re-evaluation after 12 months if symptoms return.
nSTRIDE is not covered under OHIP. Some extended health plans may provide partial reimbursement—please inquire with your provider.
Some patients notice improvement within 2–4 weeks. Peak effects are typically seen within 2–3 months.